aluates Reports

$ 0.0

Automative

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2026

Published Date: 2026-01-19

Report Code: QYRE-Auto-34Y65

Global Glucagon Like Peptide 1 GLP 1 Agonists Market Insights and Forecast to 2028

BUY CHAPTERS

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2026

Code: QYRE-Auto-34Y65

Report

2026-01-19

Pages:110

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Astrazeneca plc

GSK

Sanofi

Novo Nordisk

Eli Lilly

Hanson

Shanghai Benemae

Glucagon Like Peptide-1 (GLP-1) Agonists Market Size

The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 131910 million in 2025 and is anticipated to reach US$ 597890 million by 2032, at a CAGR of 24.5% from 2026 to 2032.

Glucagon Like Peptide-1 (GLP-1) Agonists Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Glucagon Like Peptide-1 (GLP-1) Agonists competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:

Market Drivers:

Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.

Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.

Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.

Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.

Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.

Market Challenges:

High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.

Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.

Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.

Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.

Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.

Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.

This report delivers a comprehensive overview of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists. The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Glucagon Like Peptide-1 (GLP-1) Agonists market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Glucagon Like Peptide-1 (GLP-1) Agonists Market Report

Report Metric	Details
Report Name	Glucagon Like Peptide-1 (GLP-1) Agonists Market
Accounted market size in 2025	US$ 131910 million
Forecasted market size in 2032	US$ 597890 million
CAGR	24.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Dulaglutide Exenatide Liraglutide Benaglutide Other
by Application	Diabetes Obesity
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Glucagon Like Peptide-1 (GLP-1) Agonists sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Glucagon Like Peptide-1 (GLP-1) Agonists Market growing?

Ans: The Glucagon Like Peptide-1 (GLP-1) Agonists Market witnessing a CAGR of 24.5% during the forecast period 2026-2032.

What is the Glucagon Like Peptide-1 (GLP-1) Agonists Market size in 2032?

Ans: The Glucagon Like Peptide-1 (GLP-1) Agonists Market size in 2032 will be US$ 597890 million.

Who are the main players in the Glucagon Like Peptide-1 (GLP-1) Agonists Market report?

Ans: The main players in the Glucagon Like Peptide-1 (GLP-1) Agonists Market are Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae

What are the Application segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists Market report?

Ans: The Applications covered in the Glucagon Like Peptide-1 (GLP-1) Agonists Market report are Diabetes, Obesity

What are the Type segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists Market report?

Ans: The Types covered in the Glucagon Like Peptide-1 (GLP-1) Agonists Market report are Dulaglutide, Exenatide, Liraglutide, Benaglutide, Other

1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview

1.1 Product Definition

1.2 Glucagon Like Peptide-1 (GLP-1) Agonists by Type

1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Type: 2025 vs 2032

1.2.2 Dulaglutide

1.2.3 Exenatide

1.2.4 Liraglutide

1.2.5 Benaglutide

1.2.6 Other

1.3 Glucagon Like Peptide-1 (GLP-1) Agonists by Application

1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Application: 2025 vs 2032

1.3.2 Diabetes

1.3.3 Obesity

1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts

1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2021–2032

1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2021–2032

1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Manufacturers

2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2021–2026)

2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Types and Applications

2.7 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Entry into the Industry

2.8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends

2.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue

2.8.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Scenario by Region

3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021–2032

3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021–2026

3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2027–2032

3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021–2032

3.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021–2026

3.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2027–2032

3.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country

3.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021–2032)

3.4.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country

3.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021–2032)

3.5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region

3.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021–2032)

3.6.3 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country

3.7.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021–2032)

3.7.3 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country

3.8.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021–2032)

3.8.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021–2032)

4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021–2026)

4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027–2032)

4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021–2032)

4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021–2032)

4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021–2026)

4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027–2032)

4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021–2032)

4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021–2032)

5 Segment by Application

5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021–2032)

5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021–2026)

5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027–2032)

5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021–2032)

5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021–2032)

5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021–2026)

5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027–2032)

5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021–2032)

5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 AstraZeneca

6.3.1 AstraZeneca Company Information

6.3.2 AstraZeneca Description and Business Overview

6.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.3.5 AstraZeneca Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Company Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 GSK

6.5.1 GSK Company Information

6.5.2 GSK Description and Business Overview

6.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.5.5 GSK Recent Developments/Updates

6.6 Hanson

6.6.1 Hanson Company Information

6.6.2 Hanson Description and Business Overview

6.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.6.5 Hanson Recent Developments/Updates

6.7 Shanghai Benemae

6.7.1 Shanghai Benemae Company Information

6.7.2 Shanghai Benemae Description and Business Overview

6.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

6.7.5 Shanghai Benemae Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Chain Analysis

7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process Analysis

7.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Marketing

7.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels

7.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors

7.5 Glucagon Like Peptide-1 (GLP-1) Agonists Customer Analysis

8 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics

8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends

8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers

8.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

8.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

GSK

Sanofi

Novo Nordisk

Eli Lilly

Hanson

Shanghai Benemae

List of Tables

Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation by Manufacturers in 2025

Table 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Types and Applications

Table 12. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Companies by Tier (Tier 1, Tier 2, Tier 3), based on Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (K Units), 2021–2026

Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021–2026)

Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (K Units), 2027–2032

Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2027–2032)

Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (US$ Million), 2021–2026

Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021–2026)

Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (US$ Million), 2027–2032

Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2027–2032)

Table 25. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2021–2026

Table 27. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2027–2032

Table 28. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2021–2026

Table 29. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2021–2026

Table 32. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2027–2032

Table 33. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2021–2026

Table 42. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2027–2032

Table 43. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (US$ Million), 2027–2032

Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2021–2026)

Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2027–2032)

Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021–2026)

Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2027–2032)

Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021–2026)

Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2027–2032)

Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2021–2026)

Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2027–2032)

Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2021–2026)

Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2027–2032)

Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021–2026)

Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2027–2032)

Table 64. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021–2026)

Table 67. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2027–2032)

Table 68. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2021–2026)

Table 69. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2027–2032)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 73. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Eli Lilly Company Information

Table 76. Eli Lilly Description and Business Overview

Table 77. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 78. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 79. Eli Lilly Recent Developments/Updates

Table 80. AstraZeneca Company Information

Table 81. AstraZeneca Description and Business Overview

Table 82. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 83. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 84. AstraZeneca Recent Developments/Updates

Table 85. Sanofi Company Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 88. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 89. Sanofi Recent Developments/Updates

Table 90. GSK Company Information

Table 91. GSK Description and Business Overview

Table 92. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 93. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 94. GSK Recent Developments/Updates

Table 95. Hanson Company Information

Table 96. Hanson Description and Business Overview

Table 97. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 98. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 99. Hanson Recent Developments/Updates

Table 100. Shanghai Benemae Company Information

Table 101. Shanghai Benemae Description and Business Overview

Table 102. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 103. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product

Table 104. Shanghai Benemae Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List

Table 108. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List

Table 109. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends

Table 110. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers

Table 111. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

Table 112. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Glucagon Like Peptide-1 (GLP-1) Agonists

Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type: 2025 & 2032

Figure 4. Dulaglutide Product Picture

Figure 5. Exenatide Product Picture

Figure 6. Liraglutide Product Picture

Figure 7. Benaglutide Product Picture

Figure 8. Other Product Picture

Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Application (US$ Million), 2021–2032

Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application: 2025 & 2032

Figure 11. Diabetes

Figure 12. Obesity

Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Million), 2021–2032

Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), 2021–2032

Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit), 2021–2032

Figure 17. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered

Figure 18. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers in 2025

Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers in 2025

Figure 20. Top 5 and Top 10 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players: Market Share by Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists in 2025

Figure 21. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 23. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021–2032)

Figure 24. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021–2032)

Figure 25. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 26. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 27. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021–2032)

Figure 28. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021–2032)

Figure 29. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021–2032)

Figure 35. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021–2032)

Figure 36. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. China Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021–2032)

Figure 47. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021–2032)

Figure 48. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021–2032)

Figure 52. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021–2032)

Figure 53. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. U.A.E Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Global Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2021–2032)

Figure 57. Global Revenue Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2021–2032)

Figure 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2021–2032)

Figure 59. Global Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2021–2032)

Figure 60. Global Revenue Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2021–2032)

Figure 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2021–2032)

Figure 62. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025

GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Receptor Agonist Drugs Market Research Report 2024

Global GLP 1 Agonists for Obesity Market Research Report 2024

Global Oral GLP 1 Agonist Market Research Report 2024

Global GLP 1 Agonist Injection Market Research Report 2024

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

Global GLP 1 Receptor Antagonist Market Research Report 2024

GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Drugs Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA Therapy Market Research Report 2024

Global GLP 1 Drug Peptide API Market Research Report 2024

Global GIP 1 Receptor Agonist Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global GLP 1 Injection Market Research Report 2024

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global GLP 1 Peptide Drugs Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions